Pieris’s Anticalin could be a Gamechanger!
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) develops Anticalin-based drugs for treatment of conditions related to immuno-oncology and respiratory diseases such as Asthma and Anaemia. Anticalin proteins are engineered versions of lipocalins that are human proteins having the ability to bind, store and transport molecules, which the Company has...
